One of the promising methods of treatment of gene-based disorders is a gene therapy that might be applied for the treatment of numerous diseases, including cancers of cardiovascular system, e.g. chronic lymphoid leukemia. However, genetic material delivering to a target destination is difficult due to high exposure of nucleic acid molecules for enzymatic degradation. Thus, it is necessary to use transportation system, which will contribute to the efficient, directed delivery of the genetic drug to the target cell, therefore increasing the efficiency of the therapy.
The offer comprises the production technology of new, antibody-conjugate liposomal carriers containing antisense oligonucleotides to be applied in the gene therapy.
Our immunoliposomes show a long-term stability as well as high selectivity and efficiency in delivering drugs into the cancer cells. They successfully protect enclosed genetic material against enzymatic digestion. Liposomes according to the invention allow improvement in leukemia treatment efficiency with the use of antisense therapy and enable encapsulation of various types of genetic drugs (As-ODNs, siRNA, shRNA, miRNA, DNAzymes). Developed technology enables conjugation of targeting antibodies to the liposomes. Thus obtained preparations might be applied along with commonly used cytostatics
- Target gene therapy
- Anticancer therapy
- Carriers of genetic drugs
Posted by Agata Kołacz, Posted on 19.05.2016